Citations

Clear

3942 citation(s) found for "To, Van".

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report
Al‐Samkari, Hanny , Kasthuri, Raj S. , Mager, Hans‐Jurgen, Zhou, Jenny Y. , Serra, Marcelo M. , Samuelson‐Bannow, Bethany T., Doren, Layla N Van , Piccirillo, Jay F. , Clancy, Marianne S. , Thomas, Sonia , Riera‐Mestre, Antoni , Gossage, James R. , Hermans, Cédric , Hammill, Adrienne M. , Drygalski, Annette von , Olitsky, Scott E., Faughnan, Marie E. , Sewaralthahab, Sarah , Iyer, Vivek N , Al-Samkari, Hanny , Hammill, Adrienne , Kasthuri, Raj S , Thomas, Sonia M , McCrae, Keith R. , Pishko, Allyson M. , Iyer, Vivek , Winship, Ingrid , Mei‐Zahav, Meir

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 10 | Pages: 1813-1827

10.1002/ajh.70011 | PMID 40662351 Get It

ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
Cost-Effectiveness Analysis of Mepitel Film for Prevention of Acute Radiation Dermatitis in Breast Cancer: a Canadian Healthcare Perspective
Tse, Shirley S.W., Wong, Henry C.Y., Charbonneau, Flay, Cao, Jeffrey , Waddle, Mark R. , Wolf, Julie Ryan , Corbin, Kimberly S. , Wong, Cindy, BNurs, Raymond J Chan, Hill, Rosemary, Tse, Shirley S. W. , Wong, Henry C. Y. , Hijal, Tarek , Kerba, Marc , Lee, Shing Fung, Sonis, Stephen T. , Hurk, Corina van den, Marta, Gustavo Nader , Chan, Raymond J. , Herst, Patries M. , Chow, Edward

Mayo Clinic

No container title available | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6865024/v1 Get It

Abstract Introduction While randomized clinical trials (RCT) confirmed superiority of Mepitel film (MF) in reducing acute radiation dermatitis (ARD) compared to standard-of-care (SoC), the incremental cost difference has limited its use. A cost-effectiveness analysis (CEA) was conducted from a Canadian healthcare payer’s perspective to guide policy decisions. Methods: A decision model was constructed to perform a CEA for MF compared to SoC (moisturisers) for prevention of grade 2 or higher ARD following adjuvant hypo-fractionated whole-breast radiotherapy (RT) based on a Canadian multicentre RCT. Direct and indirect cost data were collected from two oncology centres in Canada. Quality-of-life (QoL) utility values were derived from mapping Dermatology Life Quality Index (DLQI) scores for patients with grade 2 or higher ARD at week 6 of RT to EQ-5D. A willingness-to-pay (WTF) threshold of CAD 50,000 per quality-adjusted life years (QALY) gained was used. One-way sensitivity analysis was performed to account for uncertainty in decision model assumptions. Results: Base case analysis demonstrated that MF is cost-effective in preventing grade 2 or higher ARD as compared with SoC with an incremental cost-effectiveness ratio (ICER) of CAD 3,366 per QALY gained. When nursing costs were included, MF resulted in an ICER of CAD 2,823 per QALY gained. One-way sensitivity analysis showed that the results were most sensitive to the QoL utility value for ARD. All sensitivity variations remained well below the WTP threshold. Conclusions: MF is a cost-effective intervention for preventing high-grade ARD and should be recommended for patients with breast cancer undergoing adjuvant RT.
O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
Hallak, Hana , Chalouhi, Nohra , Gross, Bradley A. , Satomi, Junichiro, Levitt, M, Sheehan, Jason , Zipfel, Gregory J. , Chatterjee, A, Gross, Bradley , Dijk, J Van, Bulters, Diederik , Hayakawa, M. , Lanzino, Giuseppe , Levitt, M, Alaraj, Ali , Osbun, Joshua W

Mayo Clinic

SNIS 22nd annual meeting oral abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A33-A34

10.1136/jnis-2025-snis.39 Get It

Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Thalamocortical network neuromodulation for epilepsy
Osman, Gamaleldin , Starnes, Keith , Sheffield, W. D., Leyde, Kent, Stead, Matt, Brinkmann, Benjamin H. , Miller, Kai J. , Gregg, Nicholas M. , Alcalá-Zermeño, Juan Luis , Osman, Gamaleldin M, Brinkmann, Benjamin H , Lundstrom, Brian Nils , Gregg, Nicholas M , Starnes, Donnie Keith , Agashe, Shruti , Sheffield, W Douglas, Stead, Matt, Gompel, Jamie J. Van , Worrell, Gregory A. , Lundstrom, Brian N.

Mayo Clinic

Brain Communications | July 11, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcaf270 | PMID 40980408 Get It

Abstract Despite the growing interest in network-guided neuromodulation for epilepsy, uncertainty about the safety and long-term efficacy of thalamocortical stimulation persists. Our evaluation focused on the use of a four-lead open-loop implantable pulse generator for thalamocortical network neuromodulation. We retrospectively reviewed seven patients with diverse seizure networks—poorly localized, regional, or multifocal—undergoing thalamocortical neuromodulation. Employing a four-lead system, electrodes targeted both thalamic and cortical seizure network nodes. We assessed seizure severity, life satisfaction and sleep quality on a 10-point scale, and seizure frequency was assessed via telephone interviews and chart review. Outcomes were assessed by the Wilcoxon sign-rank test at the 0.05 significance level. Seven patients with a median age at implant of 22 years (range 14–42 years) had a median disabling seizure reduction of 93% (range 50–100%, P = 0.0156), with 100% responder rate (≥50% reduction in seizure frequency) after a median of 17 months post-implantation (range 13–60). The median improvement in seizure severity was 3.5 out of 10 points (P = 0.0312), life satisfaction 4.5 points (P = 0.0312) and quality of sleep 3 points (P = 0.062). No perioperative complications occurred. Transient seizure exacerbations (n = 2) and stimulation-related sensory/motor side-effects (n = 2) quickly resolved with parameter adjustments. One patient required surgical revision due to delayed infection. Six patients had permanent electrode placement refined by intracranial EEG trial stimulation; five patients had >90% reduction in seizure frequency during trial stimulation. Thalamocortical network neuromodulation using a four-lead open-loop system is safe and associated with significant improvements in seizure control and patient quality of life. Trial stimulation during intracranial EEG shows promise for enhancing seizure network engagement and parameter optimization but requires further study. Prospective controlled trials are needed to further characterize and validate the efficacy and side-effect profile of thalamocortical network neuromodulation for epilepsy.
Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization
Fabre, Valeria , Hsu, Yea‐Jen , Carroll, Karen C. , Salinas, Alejandra , Abbo, Lilian M. , Bower, Chris , Berry, J. Michael, Degnan, Kathleen, Dhaubhadel, Pragya, Dress, Marci, Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glasser, Laurel J., Johnson, J. Kristie, Karaba, Sara M. , Kubischta, Alyssa, Landrum, B. Mark, Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Qasba, Sonia, Rittmann, Barry , Robinson, Evan D. , Rosa, Rossana , Salinas, Jorge , Shah, Aditya , Schrank, Gregory M. , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Virk, Zunaira, Cosgrove, Sara E. , Abbo, Lilian M , Karaba, Sara M , Fabre, Valeria , Milstone, Aaron M. , Berry, Jennifer, Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Glasser, Laurel J., Howard‐Anderson, Jessica , Kim, Justin , Mathers, Amy J. , Moehring, Rebekah W. , O’Horo, John C. , Rodriguez‐Nava, Guillermo , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van , Gadala, Avinash

Mayo Clinic

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00530-25 | PMID 40643261 Get It

ABSTRACT Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship. IMPORTANCE Blood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.
Type 1 Diabetes Autoantibodies in Acute, Recurrent Acute, and Chronic Pancreatitis
Wasserfall, Clive , Forsmark, Chris E. , Li, Liang , Hart, Phil A. , Goodarzi, Mark O. , Kudva, Yogish C. , Yadav, Dhiraj , Conwell, Darwin L. , Andersen, Dana K. , Casu, Anna , Cusi, Ken, Fogel, Evan L. , Park, Walter G. , Wasserfall, Clive H , Li, Shuang , Bellin, Melena D. , Conwell, Darwin L. , Serrano, Jose, Fisher, William P. , Hughes, Steven J. , Van Den Eeden, Stephen K

Mayo Clinic

Diabetes | July 9, 2025 | Volume: 74 | Issue: 9 | Pages: 1603-1612

10.2337/db24-0931 | PMID 40633067 Get It

Pancreatogenic or type 3c diabetes, which occurs as a consequence of pancreatitis, may have several mechanisms. Mechanisms overlapping with those of type 2 diabetes have been explored, including insulin resistance and insulin deficiency. However, autoimmune mechanisms in response to unmasking β-cell antigens, similar to those of type 1 diabetes (T1D), have not been thoroughly examined. We performed cross-sectional T1D autoantibody profiling in a large prospective cohort (N = 927) of adults with acute, recurrent acute, or chronic pancreatitis. We examined correlations of prevalence of autoantibodies against GAD (GAD antibody), IA-2 (IA-2 antibody), zinc transporter 8 (ZnT8; ZnT8 antibody), and insulin (insulin autoantibody [IAA]) with clinical and demographic features, including presence of diabetes, diabetes treatment, and family history of diabetes. Diabetes was present in 11 (12%) of 94 participants with acute pancreatitis, 69 (27%) of 273 with recurrent acute pancreatitis, and 235 (43%) of 560 with chronic pancreatitis. Among these groups, islet autoantibodies were respectively found in five (5.3%) of 94, 48 (17.6%) of 273, and 127 (22.6%) of 560. The proportions of individuals with diabetes who were autoantibody positive were 45%, 70%, and 54%, respectively (most commonly IAA, which may reflect exogenous insulin use). However, across the entire cohort, 27 participants (2.9%) had two, two (0.2%) had three, and one (0.1%) had four T1D-associated autoantibodies, respectively, suggesting a potential pathogenic link that should be further explored. ARTICLE HIGHLIGHTS Type 1 diabetes–associated autoimmune mechanisms have not been thoroughly examined in pancreatitis-associated diabetes. We assessed the prevalence of four islet autoantibodies in serum from a large prospective cohort of patients with acute, recurrent acute, or chronic pancreatitis. Diabetes was present in 11 (12%) of 94 participants with acute pancreatitis, 69 (27%) of 273 with recurrent acute pancreatitis, and 235 (43%) of 560 with chronic pancreatitis. Excluding those with only insulin autoantibody positivity, which is confounded by insulin treatment, islet autoantibodies were identified in 51 (5.5%) of 927 participants, and 30 (3.2%) of 297 were positive for two or more autoantibodies. Our findings suggest pancreatitis may elicit islet autoimmunity in a subset of patients, necessitating prospective longitudinal follow-up.
Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis
Jin, Zhaohui , Hubbard, Joleen M. , Eng, Cathy , Lieu, Christopher H. , Douillard, Jean‐Yves , Adams, Richard , Maughan, Tim , Cutsem, Eric Van , Venook, Alan P. , Lenz, Heinz‐Josef , Heinemann, Volker , Schmoll, H.J.E-V., Fuchs, Charles S. , Hecht, J. Randolph , Punt, Cornelis J. A. , Bokemeyer, Carsten , Gramont, Aimery de , Venook, Alan P , Maughan, Timothy S , Hubbard, Joleen , Adams, Richard , Van Cutsem, Eric , Lieu, Christopher , Jin, Zhaohui , Eng, Cathy , Dixon, Jesse G. , Stintzing, Sebastian , Saltz, Leonard B. , Falcone, Alfredo , Díaz‐Rubio, Eduardo , Punt, Cornelis J.A. , Tebbutt, Niall C. , Chibaudel, Benoist , Zalcberg, John , Yoshino, Takayuki , Shi, Qian

Mayo Clinic

JCO Oncology Advances | July 9, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-24-00080 Get It

PURPOSE Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (<50 years, named early-onset CRC [eoCRC]) has been increasing. PATIENTS AND METHODS Individual patient data on 13,365 patients with metastatic CRC enrolled between 2000 and 2012 in 17 first-line randomized trials in the Aide et Recherche en Cancérologie Digestive database were pooled. The distribution of demographics, clinicopathologic features, biomarkers, and outcome data were summarized and compared by age groups. Progression-free survival (PFS) and overall survival (OS) were assessed by Kaplan-Meier curves and Cox models stratified by treatment arms within studies, adjusting for potential confounders. Predictive value of age group on clinical outcomes was evaluated by testing interaction effect between treatment and age variables. RESULTS Overall, 2,045 patients with eoCRC (median age, 42.5) and 11,320 patients with average-onset CRC (aoCRC; median age, 63.8) were included in this analysis. Within the eoCRC population, treatment with bevacizumab in addition to chemotherapy improved PFS (9.9 v 6.8 months; hazard ratio [HR], 0.66 [95% CI, 0.54 to 0.80]; P < .0001), which was similar to the findings in aoCRC population (9.4 v 7.3 months; HR, 0.73 [95% CI, 0.67 to 0.80]; P < .001; interaction P = .5415). However, epithelial growth factor receptor inhibitor (EGFRi) did not improve PFS in RAS wild-type (WT) patients with eoCRC who had left-sided primary tumors (8.3 v 8.9 months; HR, 1.20 [95% CI, 0.81 to 1.77]; P = .36), whereas EGFRi significantly improved PFS in the aoCRC population (9.9 v 8.5 months; HR, 0.74 [95% CI, 0.64 to 0.86]; P < .0001; interaction P = .083). CONCLUSION Treatment-naïve patients with metastatic eoCRC appear to derive similar benefit from bevacizumab as patients with aoCRC. However, patients with eoCRC with left-sided RAS/RAF WT tumors did not appear to derive benefit from first-line EGFRi.